Your browser doesn't support javascript.
loading
Naoxintong capsule for treating cardiovascular and cerebrovascular diseases: from bench to bedside.
Zhang, Wei-Jian; Chen, Rui-Qi; Tang, Xuan; Li, Pei-Bo; Wang, Jian; Wu, Hai-Ke; Xu, Ning; Zou, Ming-Fei; Luo, Sen-Rong; Ouyang, Zi-Qi; Chen, Zhi-Kai; Liao, Xu-Xing; Wu, Hao.
Afiliación
  • Zhang WJ; Department of Neurosurgery, First People's Hospital of Foshan, Foshan, Guangdong, China.
  • Chen RQ; Guangdong Engineering and Technology Research Center for Quality and Efficacy Reevaluation of Post-market Traditional Chinese Medicine, Guangdong Key Laboratory of Plant Resources, School of Life Sciences, Sun Yat-sen University, Guangzhou, China.
  • Tang X; Guangdong Engineering and Technology Research Center for Quality and Efficacy Reevaluation of Post-market Traditional Chinese Medicine, Guangdong Key Laboratory of Plant Resources, School of Life Sciences, Sun Yat-sen University, Guangzhou, China.
  • Li PB; Guangdong Engineering and Technology Research Center for Quality and Efficacy Reevaluation of Post-market Traditional Chinese Medicine, Guangdong Key Laboratory of Plant Resources, School of Life Sciences, Sun Yat-sen University, Guangzhou, China.
  • Wang J; Department of Neurosurgery, Foshan Sanshui District People's Hospital, Foshan, Guangdong, China.
  • Wu HK; Department of Neurology, Foshan Hospital of Traditional Chinese Medicine, Foshan, Guangdong, China.
  • Xu N; Second People's Hospital of Foshan, Foshan, Guangdong, China.
  • Zou MF; Second People's Hospital of Foshan, Foshan, Guangdong, China.
  • Luo SR; Guangdong Medical University, Zhanjiang, Guangdong, China.
  • Ouyang ZQ; Guangdong Medical University, Zhanjiang, Guangdong, China.
  • Chen ZK; Guangdong Medical University, Zhanjiang, Guangdong, China.
  • Liao XX; Department of Neurosurgery, First People's Hospital of Foshan, Foshan, Guangdong, China.
  • Wu H; Guangdong Engineering and Technology Research Center for Quality and Efficacy Reevaluation of Post-market Traditional Chinese Medicine, Guangdong Key Laboratory of Plant Resources, School of Life Sciences, Sun Yat-sen University, Guangzhou, China.
Front Pharmacol ; 15: 1402763, 2024.
Article en En | MEDLINE | ID: mdl-38994201
ABSTRACT
Naoxintong Capsule (NXT), a renowned traditional Chinese medicine (TCM) formulation, has been broadly applied in China for more than 30 years. Over decades, accumulating evidences have proven satisfactory efficacy and safety of NXT in treating cardiovascular and cerebrovascular diseases (CCVD). Studies have been conducted unceasingly, while this growing latest knowledge of NXT has not yet been interpreted properly and summarized comprehensively. Hence, we systematically review the advancements in NXT research, from its chemical constituents, quality control, pharmacokinetics, to its profound pharmacological activities as well as its clinical applications in CCVD. Moreover, we further propose specific challenges for its future perspectives 1) to precisely clarify bioactivities of single compound in complicated mixtures; 2) to evaluate the pharmacokinetic behaviors of NXT feature components in clinical studies, especially drug-drug interactions in CCVD patients; 3) to explore and validate its multi-target mechanisms by integrating multi-omics technologies; 4) to re-evaluate the safety and efficacy of NXT by carrying out large-scale, multicenter randomized controlled trials. In brief, this review aims to straighten out a paradigm for TCM modernization, which help to contribute NXT as a piece of Chinese Wisdom into the advanced intervention strategy for CCVD therapy.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Front Pharmacol Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Front Pharmacol Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Suiza